Fortrea Holdings (FTRE) Total Non-Current Liabilities (2022 - 2026)
Fortrea Holdings (FTRE) reported Total Non-Current Liabilities of $2.1 billion for Q1 2026, down 4.78% on a YoY basis from $2.2 billion in Q1 2025, and little changed quarter-over-quarter from $2.1 billion in Q4 2025.
Fortrea Holdings (FTRE) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Total Non-Current Liabilities for 5 years, with the latest figure at $2.1 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 4.78% year-over-year to $2.1 billion; the trailing twelve-month figure through Mar 2026 stood at $2.1 billion (down 4.78% YoY), and the FY2025 full-year result was $2.1 billion, down 3.14% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $2.1 billion, roughly flat from $2.1 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $2.6 billion in Q1 2024, with the low at $923.6 million in Q4 2022.
- Historically, Total Non-Current Liabilities has averaged $2.2 billion across 5 years, with a median of $2.2 billion in 2024.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 180.03% — and 2024, when it fell 19.21%.
- Fortrea Holdings' Total Non-Current Liabilities stood at $923.6 million in 2022, then jumped by 180.03% to $2.6 billion in 2023, then slipped by 15.65% to $2.2 billion in 2024, then slipped by 3.14% to $2.1 billion in 2025, then grew by 0.32% to $2.1 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $2.1 billion (Q1 2026), $2.1 billion (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | 2.12 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.12 Bn |
| Dec 31, 2025 | 2.11 Bn |
| Sep 30, 2025 | 2.12 Bn |
| Jun 30, 2025 | 2.21 Bn |
| Mar 31, 2025 | 2.23 Bn |
| Dec 31, 2024 | 2.18 Bn |
| Sep 30, 2024 | 2.11 Bn |
| Jun 30, 2024 | 2.07 Bn |
| Mar 31, 2024 | 2.62 Bn |
| Dec 31, 2023 | 2.59 Bn |
| Sep 30, 2023 | 2.59 Bn |
| Jun 30, 2023 | 2.57 Bn |
| Dec 31, 2022 | 923.60 Mn |